Clinical trial · Interventional
Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer
A Multicentre, Randomized Study of Trastuzumab Combined With Chemotherapy or Endocrine Therapy as the First Line Treatment for Patients With Metastatic Luminal B2 Breast Cancer Subtype
NCT01950182CI-TRIAL-00045978SYSUCC-002completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic Luminal B2 breast cancer subtype randomised to treatment with Trastuzumab Combined With Chemotherapy or Endocrine Therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy combined with trastuzumab | Drug | — | UNRESOLVED |
| Endocrine therapy combined with trastuzumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Palliative chemotherapy
- description
- Chemotherapy combined with trastuzumab. Chemotherapy could use the following drugs such as capecitabine , Vinorelbine, or Gemcitabine.
- interventionNames
- Drug: Chemotherapy combined with trastuzumab
- type
- EXPERIMENTAL
- label
- Palliative endocrine therapy
- description
- Endocrine therapy combined with trastuzumab. Endocrine therapy could use tamoxifen or aromatase inhibitors including anastrozole, letrozole, or exemestane.
- interventionNames
- Drug: Endocrine therapy combined with trastuzumab
Primary outcomes (1)
- measure
- progression-free survival (PFS)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18 years or older. 2. Patients with an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. 3. Histologically confirmed metastatic or local recurrence of breast cancer. 4. ER positive and/or progesterone receptor (PR) positive, HER-2+ defined as immuno-histochemistry3+ staining or FISH+. 5. Prior adjuvant Trastuzumab therapy is permitted, but disease-free interval (DFI) must be more than 12 months. 6. Patients must have measurable or evaluable disease. 7. Adequate bone marrow reserve with neutrophils \> 1000 and platelets \> 100,000. 8. Adequate renal function with serum creatinine \< 2.0. 9. Adequate hepatic reserve with serum bilirubin \< 2.0, alanine transaminase(ALT) \< 3 times the upper limit of normal, and alkaline phosphatase \< 5 times the upper limit of normal. 10. Adequate cardiac reserve with at least 45% of Left ventricular ejection fraction (LVEF) by echocardiogram. 11. Able to give informed consent. 12. Life expectancy of at least 12 weeks. Exclusion Criteria: 1. Pregnant or breast feeding. 2. ECOG score ≧2 3. DFI \<12 months. 4. LVEF \< 45% by echocardiogram. 5. Uncontrolled medical problems. 6. Evidence of active acute or chronic infection. 7. Hepatic, renal, or bone marrow dysfunction as detailed above. 8. Concurrent malignancy or history of other malignancy within the last five years except as noted above. 9. Known severe hypersensitivity to Trastuzumab. 10. Patients were unable or unwilling to comply with program requirements.
References
Publications (0)
Data not yet available
No reference posted for this study.